Big Pharma's clinical trials in China are quietly bypassing global oversight, raising urgent alarms about data transparency and ethical practices. This emerging gap poses a serious risk to the trust and integrity of drug approvals worldwide
Big Pharma's clinical trials in China are quietly bypassing global oversight, raising urgent alarms about data transparency and ethical practices. This emerging gap poses a serious risk to the trust and integrity of drug approvals worldwide
Advocacy groups are urging regulators to launch a bold anticompetition probe into Big Pharma's moves after Brexit, accusing the industry of manipulating the market and driving prices sky-high. This call highlights growing concerns over pharmaceutical practices in the evolving post-Brexit landscape
